Abstract
A family of 20 tris-azaaromatic quaternary ammonium (AQA) compounds were tested for their inhibition of α7 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus laevis oocytes. The potency of inhibitory activity was related to the hydrophobic character of the tris head groups. Two tris-AQA compounds were studied in detail: the highly effective inhibitor 1,3,5-tri-[5-(1-quinolinum)-pent-1-yn-1-yl]-benzene tribromide (tPyQB) and the less potent antagonist 1,3,5,-tri-{5-[1-(2-picolinium)]-pent-1-yn-1-yl}benzene tribromide (tPy2PiB). In addition, we evaluated 1,2,4,5-tetra-{5-[1-(3-benzyl)pyridinium]pent-1-yl}benzene tetrabromide (tkP3BzPB), a tetrakis-AQA with very hydrophobic headgroups. We compared the activity of the AQA compounds to the frequently used α7-antagonist methyllycaconitine (MLA). Both tPyQB and tkP3BzPB were selective antagonists of α7. However, although inhibition by tPyQB was reversible within 5 min, the recovery time constant for tkP3BzPB inhibition was 26.6 ± 0.8 min, so that the equilibrium inhibition in the prolonged presence of nanomolar concentrations of tkP3BzPB was nearly 100%. The potency, selectivity, and slow reversibility of tkP3BzPB were comparable with or greater than that of MLA. The inhibitory actions of tPyQB, tPy2PiB, and tkP3BzPB were evaluated on the acetylcholine (ACh)-evoked responses of native nAChRs in rat brain slices. The α7-mediated responses of hippocampal interneurons were effectively reduced by 1 μM tPyQB and tkP3BzPB but not tPy2PiB. In rat medial septum, tkP3BzPB produced a greater inhibition of ACh-evoked responses of cells with fast inward currents (type I) than of cells with predominantly slow kinetics (type II), suggesting that tkP3BzPB can block α7 yet preserve the responsiveness of non-α7 receptors. These agents might be helpful in elucidating complex receptor responses in brain regions with mixed populations of nAChRs.
Footnotes
- Received March 12, 2009.
- Accepted June 25, 2009.
This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grant U19-DA017548], the National Institutes of Health National Institute of General Medical Sciences[Grant R01-GM057481], and the National Institutes of Health National Institute on Aging [Grants P01-AG010485, T32-AG000196].
A portion of this work was previously presented in abstract form: López GY, Thinschmidt JS, Zheng G, Zhang Z, Crooks PA, Dwoskin LP, and Papke RL. Differential inhibition of ACh-evoked responses of neuronal nicotinic receptors in rat brain slices by selective nAChR antagonists. Society for Neuroscience Satellite Symposium on “Nicotinic Acetylcholine Receptors as Therapeutic Targets—Emerging Frontiers in Basic Research and Clinical Science”; San Diego, CA; 2007 Oct 31-Nov 2; Poster 1.31.
The University of Kentucky holds patents on the tris- and tetrakis-azaaromatic quaternary ammonium compounds described herein. A potential royalty stream to L.P.D. and P.A.C. may occur consistent with University of Kentucky policy.
ABBREVIATIONS: nAChR, nicotinic acetylcholine receptor; CNS, central nervous system; MS/DB, medial septum/diagonal band; MLA, methyllycaconitine; tPy2PiB, 1,3,5,-tri-{5-[1-(2-picolinium)]-pent-1-yn-1-yl}benzene tribromide; tPyQB, 1,3,5-tri-[5-(1-quinolinum)-pent-1-yn-1-yl]-benzene tribromide; tkP3BzPB, 1,2,4,5-tetra-{5-[1-(3-benzyl)pyridinium]pent-1-yl}benzene tetrabromide; AQA, azaaromatic quaternary ammonium; PNU-120596, 1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxanol-3-yl)-urea; ACh, acetylcholine; DHβE, dihydro-β-erythroidine; 5-HT, 5-hydroxytryptamine; TMPH, 2,2,6,6-tetramethylpiperidin-4-yl heptanoate; GTS-21, 3-2,4,dimethoxy-benzylidene anabaseine; VTA, ventral tegmental area.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|